BioNTech SE American Depositary Share
BNTX Real Time Price USDRecent trades of BNTX by members of U.S. Congress
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by BNTX's directors and management
No recent Insider Trading for this ticker
Insider Trading DashboardGovernment lobbying spending instances
No Corporate Lobbying instances for this ticker
Corporate Lobbying DashboardEstimated quarterly lobbying spending
No Corporate Lobbying data for this ticker
Corporate Lobbying DashboardNew patents grants
-
Patent Title: Coronavirus vaccine Nov. 05, 2024
-
Patent Title: Preparation and storage of liposomal rna formulations suitable for therapy Aug. 13, 2024
-
Patent Title: Stabilization of poly(a) sequence encoding dna sequences Aug. 06, 2024
-
Patent Title: Substituted imidazoquinolines Aug. 06, 2024
-
Patent Title: Substituted imidazoquinolines as agonists of tlr7 May. 21, 2024
-
Patent Title: Rna constructs and uses thereof Apr. 09, 2024
-
Patent Title: Monoclonal antibodies directed against programmed death-1 protein and their use in medicine Mar. 19, 2024
-
Patent Title: Coronavirus vaccine Mar. 12, 2024
-
Patent Title: Methods for characterizing loss of antigen presentation Mar. 05, 2024
-
Patent Title: Coronavirus vaccine Jan. 23, 2024
-
Patent Title: Method for reducing immunogenicity of rna Jan. 16, 2024
-
Patent Title: Nucleic acid molecules encoding binding agents to cd40 and 4-1bb (cd137) Nov. 14, 2023
-
Patent Title: Diagnosis and therapy of cancer involving cancer stem cells Oct. 24, 2023
-
Patent Title: Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases Oct. 17, 2023
-
Patent Title: Rna constructs and uses thereof Oct. 10, 2023
-
Patent Title: Human monoclonal antibodies to ganglioside gd2 Sep. 19, 2023
-
Patent Title: Rna for treatment of autoimmune diseases Jul. 18, 2023
-
Patent Title: Particles comprising a shell with rna May. 30, 2023
-
Patent Title: Coronavirus vaccine Jan. 10, 2023
-
Patent Title: Individualized vaccines for cancer Nov. 22, 2022
-
Patent Title: 3′-utr sequences for stabilization of rna Nov. 08, 2022
-
Patent Title: Methods and compositions for stimulating immune response Oct. 18, 2022
-
Patent Title: Preparation and storage of liposomal rna formulations suitable for therapy Jul. 26, 2022
-
Patent Title: Formulation for administration of rna May. 03, 2022
-
Patent Title: Recombinant vaccines and use thereof Apr. 12, 2022
-
Patent Title: Predicting immunogenicity of t cell epitopes Jan. 11, 2022
-
Patent Title: Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof Jun. 29, 2021
-
Patent Title: Cytotoxic immunostimulating particles and uses thereof Apr. 20, 2021
-
Patent Title: Agonistic tumor necrosis factor (tnf) receptor binding agents Feb. 23, 2021
-
Patent Title: Particles comprising protamine and rna in combination with endosome destabilizing agents Aug. 04, 2020
-
Patent Title: Agents for treatment of claudin expressing cancer diseases Jul. 21, 2020
-
Patent Title: Hydrogen water generator May. 26, 2020
-
Patent Title: Methods of inducing t cell activation by administering an antibody comprising cd40 and 4-1bb (cd137) binding domains Oct. 29, 2019
-
Patent Title: Compositions and methods for diagnosis and treatment of cancer Aug. 06, 2019
-
Patent Title: Identification of surface-associated antigens for tumor diagnosis and therapy May. 28, 2019
-
Patent Title: Identification of tumor-associated markers for diagnosis and therapy Apr. 09, 2019
-
Patent Title: Tumor antigens for determining cancer therapy Jan. 29, 2019
-
Patent Title: Particles comprising single stranded rna and double stranded rna for immunomodulation Jan. 08, 2019
-
Patent Title: Modification of rna, producing an increased transcript stability and translation efficiency Oct. 23, 2018
-
Patent Title: Agents for treatment of claudin expressing cancer diseases Oct. 09, 2018
-
Patent Title: Site-specific antibody-mediated activation of proapoptotic cytokines: amaize (antibody-mediated apoptosis inducing cytokines) Apr. 17, 2018
-
Patent Title: Identification of tumor-associated cell surface antigens for diagnosis and therapy Mar. 06, 2018
-
Patent Title: Homo- and heterodimeric smac mimetic compounds as apoptosis inducers Aug. 15, 2017
-
Patent Title: Genetic products differentially expressed in tumors and use thereof May. 02, 2017
-
Patent Title: Particles comprising single stranded rna and double stranded rna for immunomodulation May. 02, 2017
-
Patent Title: Identification of surface-associated antigens for tumor diagnosis and therapy Jan. 03, 2017
-
Patent Title: Use of flt3 ligand for enhancing immune responses in rna immunization Nov. 08, 2016
-
Patent Title: Modification of rna, producing an increased transcript stability and translation efficiency Oct. 25, 2016
-
Patent Title: Homo- and heterodimeric smac mimetic compounds as apoptosis inducers Apr. 26, 2016
-
Patent Title: Vaccine composition comprising 5′-cap modified rna Mar. 29, 2016
Federal grants, loans, and purchases
No Government Contracts for this ticker
Government Contracts DashboardEstimated quarterly amount awarded from public contracts
Number of mentions of BNTX in WallStreetBets Daily Discussion
Recent insights relating to BNTX
Recent picks made for BNTX stock on CNBC
ETFs with the largest estimated holdings in BNTX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BNTX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.